Evaluation of Potential Drug-Drug Interactions in Hospitalized Pediatric Patients with Bronchitis Diagnosis: A Retrospective Study
,
Abstract
Background: Acute bronchitis is one of the most common infectious diseases in children and a major cause of hospital admissions. Treatment of acute bronchitis is usually symptomatic, analgesics and antipyretics are often used. The simultaneous intake of drugs brings pharmacological interactions with it. These interactions are important for the success of the treatment. The aim of our investigation is to determine the prevalence and severity of possible drug interactions; draw attention to drug interactions in children and adolescents. Methods: This study was conducted on 99 patients, 48 males and 51 females, with bronchitis hospitalized between 2019 and 2021 in Rize, Turkey. Patient records were retrospectively evaluated, and drug interactions were determined using database Medscape data by clinical pharmacists. Data was analyzed by SPSS 15.0v. statistical program p<0.05 was considered significant. The severity of the interactions was assessed as an alternative to serious use, close monitoring and minor interactions. Results: In this study, it was found that the mean age of the patients was 5.17 ± 2.31 years. A total of 69 drug-drug interactions were identified, most of which (63.6%) were identified on the ‘Close Monitor', and the interaction rate at the 'Serious Use Alternative' level was found to be 16.2%. There was no interaction in some patients in this study; but some patients experienced up to 4 interactions. Conclusion: Healthcare professionals should be more cautious about polypharmacy and more aware of the rational use of drugs. By raising awareness of drug interactions among healthcare professionals, drug interactions can be minimized.
2. Bülbül, Y. Akut bronşit tedavisi. Treatment of acute bronchitis. Avaibile from: https://verem.org.tr/uploads/pdf/23kongre/akut_bronsit.pdf Accesed May 06, 2021.
3. Carolan PL. Pediatric bronchitis. Avaibile from: https://emedicine.medscape.com/article/1001332-overview Accesed May 26, 2021.
4. Alp H, Türk S, Yılmaz S, MutluTiryaki Ü, Yiğitbaşı M. Rational drug use. Mustafa Kemal Üniversitesi Tıp Dergisi. 2018; 9(33): 20-28.
5. Karataş N, Kaya A, İşler A. Akılcı ilaç kullanımın çocuk sağlığına etkileri. The effects of rational drug use onchild health. 2 nd International Health Sciences and Life Congress. 2019
6. Baktır G, Pala Z. Çocuklarda ilaç kullanımı. Medication use in pediatrics. Meslek İçi Sürekli Eğitim Dergisi. 2012; 60-68.
7. Matthys H, Kamin W, Funk P, Heger M. Pelargonium sidoides preparation (EPs 7630) in the treatment of acute bronchitis in adults and children. Phytomedicine. 2007;14 Suppl 6:69-73.
8. Feinstein J, Dai D, Zhong W, Freedman J, Feudtner C. Potential drug-drug interactions in infant, child, and adolescent patients in children's hospitals. Pediatrics. 2015;135(1):e99-e108.
9. Yeh ML, Chang YJ, Yeh SJ, et al. Potential drug-drug interactions in pediatric outpatient prescriptions for newborns and infants. Comput Methods Programs Biomed. 2014;113(1):15-22.
10. Salerno SN, Burckart GJ, Huang SM, Gonzalez D. Pediatric Drug-Drug Interaction Studies: Barriers and Opportunities. Clin Pharmacol Ther. 2019;105(5):1067-1070.
11. Dai D, Feinstein JA, Morrison W, Zuppa AF, Feudtner C. Epidemiology of Polypharmacy and Potential Drug-Drug Interactions Among Pediatric Patients in ICUs of U.S. Children's Hospitals. Pediatr Crit Care Med. 2016;17(5):e218-e228.
12. Bebitoğlu BT, Oğuz E, Nuhoğlu Ç, et al. Evaluation of potential drug-drug interactions in a pediatric population. Turk Pediatri Ars. 2020;55(1):30-38.
13. Medina-Barajas F, Vázquez-Méndez E, Pérez-Guerrero EE, et al. Pilot study: Evaluation of potential drug-drug interactions in hospitalized pediatric patients. Pediatr Neonatol. 2020;61(3):279-289.
14. Holm J, Eiermann B, Kimland E, Mannheimer B. Prevalence of potential drug-drug interactions in Swedish pediatric outpatients. PLoS One. 2019;14(8):e0220685. Published 2019 Aug 5.
15. Chen Y, Liu J, Larson E. Temporal trends and factors associated with pediatric hospitalizations with respiratory infection. J Asthma. 2016;53(1):15-18.
16. Işık M N, Dalgıç N, Okuyan B, Yıldırmak ZY, Sancar M. Hastanede yatan pediatrik hastalarda ilaç tedavisinin incelenmesi: klinik eczacı önerileri. Evaluation of drug therapy in hospital pediatric patients: Recommandation of clinical pharmacists. J Pediatr Inf. 2020;14(4):237-243.
17. Martinbiancho J, Zuckermann J, Dos Santos L, Silva MM. Profile of drug interactions in hospitalized children. Pharm Pract (Granada). 2007;5(4):157-161.
18. Choi YH, Lee IH, Yang M, et al. Clinical significance of potential drug-drug interactions in a pediatric intensive care unit: A single-center retrospective study. PLoS One. 2021;16(2):e0246754.
19. Andrade PHS, Santos ADS, Souza CAS, Lobo IMF, da Silva WB. Risk factors for adverse drug reactions in pediatric inpatients: a systematic review. Ther Adv Drug Saf. 2017;8(6):199-210.
20. Day RO, Snowden L, McLachlan AJ. Life-threatening drug interactions: what the physician needs to know. Intern Med J. 2017;47(5):501-512.
21. Goldman RD, Vohra S, Rogovik AL. Potential vitamin-drug interactions in children: at a pediatric emergency department. Paediatr Drugs. 2009;11(4):251-7.
22. Yu SM, Kogan MD, Gergen P. Vitamin-mineral supplement use among preschool children in the United States. Pediatrics. 1997;100(5):E4.
23. Albert RH. Diagnosis and treatment of acute bronchitis. Am Fam Physician. 2010;82(11):1345-1350.
24. Alqurbi MMA, Atiah MAQ. The role of clinical pharmacists in reducing adverse drug reactions. Int J Med Developing Countries. 2020;4(1):236–239.
| Files | ||
| Issue | Vol 11, No 1 (Winter 2023) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/jpc.v11i1.12637 | |
| Keywords | ||
| Rational Drug Use; Bronchitis; Pediatrics; Drug-Drug Interaction | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
